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Background. Reports on the influence of various 
prognostic factors in carcinoma of the esophagus are con- 
flicting. The prognostic value of a set of clinicopathologic 
factors and DNA ploidy were examined in 74 patients 
with surgically resected squamous cell carcinoma of the 
lower and middle third of the esophagus. 
All patients had surgery performed in a 
single thoracic surgical unit at the Tata Memorial Hospi- 
tal between January, 1984 and December, 1987. The clini- 
copathologic factors studied were (1) gross residual dis- 
ease at operation; (2) morphology of the tumor: (3) depth 
of microscopic invasion; (4) lymph node involvement; (5) 
histologic grade; (6) vascular and lymphatic embolism; 
and (7) sex. DNA ploidy and S-phase fraction (SpF) were 
determined by flow cytometry on archival tissues ex- 
tracted from paraffin blocks. Ploidy status could be de- 
termined successfully in all 74 tumors, whereas SpF 
could be assessed only in 25. 
Of the various prognostic factors exam- 
ined with the Cox stepwise regression model, residual 
disease ( P  = O.ooo), depth of invasion ( P  = 0.047), and 
lymph node status (P = 0.077) were found to be correlated 
with overall survival. 
Conclusions. DNA ploidy was not related to prog- 
nosis. The overall survival of this group of patients at 36 
months was 28%, and median survival was 18 months. 
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Methods. 
Results. 
Key words: esophageal neoplasm, squamous cell carci- 
noma, prognosis. 
Results of treatment of symptomatic carcinoma of the 
esophagus remain unsatisfactory. The 5-year survival 
figures reported in the world literature are between 8% 
and 20%. 1,2 In Japan and in China, where cancer of the 
esophagus is endemic, early diagnosis in the presymp- 
tomatic stages by cytologic screening of high-risk popu- 
lations has, however, resulted in cure rates between 
70% and 9 0 O / 0 . ~ - ~  At the Tata Memorial Hospital, Bom- 
bay, India, nearly 800 new cases of carcinoma of the 
esophagus are registered every year. Of these, 20% of 
patients are selected for surgery, 35% are subjected to 
radiation therapy, and the remainder (45%) who pre- 
sent with advanced disease are offered only symptom- 
atic treatment. 
Clinicopathologic factors related to prognosis of 
cancer of esophagus have been studied by several 
 worker^.^,^-^ More recently, attempts have been made 
to investigate the relationship between certain biologic 
properties of the tumor, including DNA ploidy and S- 
phase fraction (SpF) and the clinical course of the dis- 
ease.''-" The results of these studies have been con- 
flicting. There is no clear consensus as to whether DNA 
ploidy and SpF are reliable prognostic factors in squa- 
mous cell carcinoma of the esophagus. We undertook 
the current study to evaluate the significance of certain 
established clinicopathologic prognostic factors, as well 
as flow cytometric assessment of ploidy status and SpF 
in relation to survival after surgery for squamous cell 
carcinoma of the lower and middle third of the esopha- 
gus. The underlying goal of the study was to identify a 
group of patients with operable tumors who potentially 
had such poor prognoses that they could be spared sur- 
gical intervention and treated by radiation therapy, che- 
motherapy, or other palliative measures. 
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Materials and Methods 
This study is based on an analysis of 74 consecutive 
patients with squamous cell carcinoma of the lower and 
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Table 1. Distribution of Prognostic Features 
Morphology 
Stenotic 8 (11) 
Ulceroproliferative 66 (89) 
Present 14 (19) 
Absent 60 (81) 
TIT2 18 (25) 
T3T4 56 (75) 
Residual disease 
Depth of invasion 
Microscopic cut margins 
Positive 4 (5) 
Negative 70 (95) 
Positive 31 (42) 
Lymph node status 
Negative 43 (58) 
Grade 
1/11 42 (57) 
111 32 (43) 
Present 6 (8) 
Absent 68 (92) 
Male 39 (52) 
Vascular and lymphatic emboli 
Sex 
Female 35 (58) 
DNA ploidy 
Aneuploid 60 (81) 
Diploid 14 (19) 
< 20% 12 (48) 
> 20% 13 (52) 
SPF 
Values in parentheses are percentages 
middle third of the esophagus who underwent surgical 
resection by the Thoracic Service A at the Tata Memo- 
rial Hospital, Bombay, India, between January, 1984 
and December, 1987. In keeping with the criteria laid 
down before the study was started, only patients who 
were residents of Bombay were included, and death 
(rather than relapse) was chosen as the end point of the 
study. This ensured that even if some patients failed to 
come for regular follow-up, their status ("dead or 
alive") could be ascertained from the well established 
Bombay Cancer Registry.*' In the event, however, there 
were only four patients who were lost to follow-up and 
were not registered with the Cancer Registry as having 
died. These four cases were excluded from survival 
analysis. 
The various clinicopathologic and biologic factors 
examined are listed in Table 1. The presence of residual 
disease was documented at surgery, as was the gross 
morphology of the tumor, which was classified as being 
either stenotic or ulceroproliferative in nature. The 
margin of surgical resection was kept at 5 cm from the 
edge of this tumor, and a limited mediastinal lymph 
node dissection was performed routinely. Lower neck 
nodes and recurrent laryngeal lymph nodes were not 
removed. Depth of invasion, lymph node status, vascu- 
lar and lymphatic embolism, and the status of cut mar- 
gins (at 5 cm) were evaluated at histologic analysis. 
DNA ploidy and SpF were analyzed on tumor tis- 
sues embedded in paraffin blocks. Flow cytometry was 
performed using a laser-based, multiparameter flow 
cytometer (Epics Profile I. Coulter, Hialeah, FL) with 
15-mW power and 488-nm excitation. Three to four 
35-pm-thick sections were cut, and single-cell suspen- 
sions were prepared according to the method described 
by Hedley et al.19 In brief, the 35-pm sections were de- 
waxed in xylene and rehydrated in descending grades 
of alcohol. The tissues were washed in distilled water, 
suspended in 0.5% pepsin in 0.9% sodium chloride at 
pH 1.5, and incubated in a water bath at 37°C with 
intermittent vortexing for 30 minutes. The suspension 
was washed with phosphate-buffered saline (PBS) at 
pH 7.2. The cells were filtered through a 35-pm nylon 
mesh and centrifuged. The pellet was treated with 0.1% 
Triton-X, incubated with RNAse, and stained with pro- 
pidium iodide (50 Wg/ml). Tumors were classified into 
diploid and aneuploid categories according to their 
DNA index (DI), which is the numerical ratio of the 
channel number of the GO/Gl peak of the experimen- 
tal sample and that of the GO/Gl peak of the standard 
diploid sample. The latter consisted of cells from paraf- 
fin-embedded, normal esophageal lymph nodes. Nor- 
mal diploid cells within the sections under study also 
were used as an internal standard. For diploid tumors, 
the D1 ranged from 0.9 to 1.1, whereas for an aneuploid 
tumor, the DI was either less than 0.9 or more than 1.1 
(Fig. 1). SpF was measured from the DNA histograms 
using a cell-cycle analysis computer software program 
(Cytologic, Coulter). Analysis was limited to samples in 
which the tumor cell population could be distinguished 
clearly from normal cells. In this study, an estimate of 
SpF was possible in 25 cases. This figure is considerably 
lower than that obtained for other solid tumors, such as 
breast cancer, in our hands and those of 
Statistical Analysis 
The various clinicopathologic and biologic prognostic 
factors that were examined were dichotomous in nature 
(Table 1). Each prognostic factor was correlated individ- 
ually with overall survival in a univariate analysis by 
the log rank test, and all together in a multivariate analy- 
sis using the stepwise Cox regression model.21 
Results 
Figure 2 shows the life table survival curve of the pa- 
tients in the study. The overall 36-month survival of 
22 CANCER July 1, 2993, Volume 72, No. 1 
I I  
DNA CONTENT DNA CONTENT 
DNA CONTENT DNA CONTENT 
Figure 1, Representative DNA histograms of paraffin-embedded 
samples of squamous cell carcinoma of the esophagus. (Top left) 
Diploid (DI = 1.0); (top right) aneuploid (DI = 1.5); (bottom left) 
aneuploid (DI = 1.7); (bottom right) aneuploid (DI = 0.7, 1.6). (Top 
left) A diploid unimodal tumor showing a single cell population 
with one GO/G1 peak and a corresponding G2 + M peak with the 
S-phase fraction between the two peaks. (Top right, bottom left, 
bottom right) Aneuploid bimodal and multimodal tumors showing 
two and more than two cell populations that are in different phases 
of the cell cycle. 
our patients was 28%, with a median figure of 18 
months. Six patients who died in the postoperative pe- 
riod were excluded from survival analysis, as were the 
four who were lost to follow-up. Table 1, which lists the 
various clinicopathologic and biologic features, shows 
that these factors were dichotomous in distribution. Ta- 
ble 1 also shows that most of the tumors were ulcero- 
proliferative in nature; only 11% were stenotic. Most 
patients in our study had advanced disease, and this is 
lo 0 0 a 6 12 18 24 30 36 42 48 54 80 86 
Months 
Figure 2. Overall survival of patients in the study. 
Table 2. Univariate Analysis of the Relationship 
Between Various Prognostic Factors and Survival 
Variable 
Residual disease 
Depth of invasion 
Lymph node status 
Morphology 
Tumor grade 
Vascular and lymphatic embolism 
Positive cut margin 
Sex 
DNA ploidy 
Chi-sauare P value 
13.1 0.0003 
6.95 0.084 
3.18 0.0746 
0.018 0.89 
0.615 0.433 
0.59 0.44 
0.305 0.58 
0.5 0.4 
0.005 0.94 
reflected by the fact that 75% of the tumors belonged to 
T3 or T4 categories, and residual disease was present 
after resection in 19% of the cases. DNA ploidy was 
measurable in all 74 tumors. Most of the tumors (8 1 %) 
were aneuploid, whereas 19% were diploid. SpF could 
be assessed in only 25 tumors. 
Table 2 gives the relationship between the various 
prognostic factors and survival from esophageal cancer 
in a univariate analysis. The only prognostic factor that 
was found to be significantly correlated with survival 
was residual disease (P = 0.0003). Two other factors, 
depth of microscopic invasion and lymph node status, 
barely failed to reach statistical significance (P  = 0.084 
and P = 0.074, respectively). DNA ploidy did not corre- 
late with survival (P = 0.94). Because SpF could be ana- 
lyzed in only 25 of the 74 cases, this parameter was not 
included in survival analysis. Table 3 presents the re- 
sults of a multivariate analysis using the Cox propor- 
tional hazard model. This analysis, which takes account 
of inherent interrelationships, if any, between the 
various prognostic factors, shows that the three prog- 
nostic factors that are independently related to survival 
are residual disease (P  = O.OOO), depth of invasion (P  = 
0.47), and lymph node metastasis (P = 0.077). 
We analyzed separately the clinicopathologic fea- 
tures of 11 patients who survived 36 months or more. 
We found no difference in the distribution of various 
prognostic factors compared to that in the entire popula- 
tion, except that of this group of 11 patients none had 
residual disease after surgery. 
Table 3. Multivariate Analysis of the Relationship 
Between Various Prognostic Factors and Survival* 
Steu no. Variable entered Chi-sauare P value 
1 Residual disease 16.83 0.000 
2 Depth of invasion 3.936 0.047 
3 Lymph node metastasis 3.137 0.077 
* Cox proportional hazard model, stepwise results. 
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Discussion 
Our result of a 28% overall survival after a mean fol- 
low-up of 36 months is a direct reflection of the rela- 
tively late stages at which cancer of the middle and 
lower third of the esophagus generally is diagnosed, 
and is comparable with figures reported in the Western 
literature.',' We found residual disease, depth of micro- 
scopic invasion, and lymph node status to be indepen- 
dent indicators of prognosis. Patients with extraesoph- 
ageal spread of the disease, postresection residual dis- 
ease, and involved lymph nodes had a significantly 
poorer prognosis (Table 3). Of the three, residual dis- 
ease had strongest prognostic influence (P = 0.0003). 
This was confirmed further by analysis of clinicopatho- 
logic features in those patients who survived for more 
than 3 years. None of them was found to have residual 
disease. 
Skinner et a1.' have shown that wall penetration 
and lymph node status are independent prognostic fac- 
tors for squamous cell carcinoma of the esophagus. Lu 
et aL6 have failed to identify depth of muscle invasion 
as a factor affecting long-term survival and have re- 
ported tumor length as a prognostic indicator. Akiyama 
and colleagues,' in a study of 1025 resected cases of 
squamous cell carcinoma of the esophagus, have found 
lymph node status to be the single most important 
prognostic factor. The 5-year survival in their node-neg- 
ative patients was 53.8%, compared to only 15.3% in 
those in whom the lymph nodes were involved, 
In our study, tumor morphology, tumor grade, vas- 
cular and lymphatic embolism, status of the micro- 
scopic cut margins, and the sex of the patient did not 
correlate with prognosis (Table 2). This is in agreement 
with the report of Skinner et al.,' who found tumor 
grade to be an insignificant prognostic factor, and that 
of Giuli and Sancho-Gamier,' who observed that the 
sex of the patient was unrelated to disease outcome. In a 
retrospective study of 2400 patients, however, Giuli 
and Gignoux' found that the 5-year prognosis was most 
favorable for patients with proliferative tumors (22%), 
intermediate for ulcerative tumors (19%), and worst for 
infiltrating lesions (12%). Our failure to observe a signif- 
icant association between tumor morphology and sur- 
vival may have been due to the relatively small number 
of patients included in our study. 
The results of DNA analysis with regard to progno- 
sis of cancer of the esophagus are conflicting."," In a 
retrospective study of 110 surgically resected cases of 
squamous cell carcinoma of the esophagus, Edwards et 
a1." reported a 70% incidence of aneuploidy, but the 
survival of these patients was similar to that in patients 
with diploid tumors. DNA ploidy did not correlate with 
other clinicopathologic factors. Matsuura et al." mea- 
sured DNA ploidy in 128 cases of esophageal carci- 
noma using a cytophotometric method. These workers 
reported that although 76.6% of patients with the an- 
euploid pattern had died by 2 years, only 34.4% with a 
diploid pattern died within this period. Our results 
agree with those of Edwards et al. in that we failed to 
observe an association between DNA ploidy status and 
survival in our group of patients. 
In summary, our study revealed that residual dis- 
ease left behind at surgery, the depth of microscopic 
invasion of tumor, and pathologic lymph node status 
are the three factors that determine prognosis for cancer 
of the esophagus. The study failed to establish that mea- 
surement of tumor DNA content by flow cytometry can 
be used to identify a subset of patients with symptom- 
atic esophageal cancer that potentially has very poor 
prognosis, and which could be spared the cost and 
trauma of surgery and treated by conservative means. 
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